Home Clinical Topics FDA approves Surfaxin to prevent respiratory distress syndrome in premature infants.

FDA approves Surfaxin to prevent respiratory distress syndrome in premature infants.

On March 6, the U.S. Food and Drug Administration (FDA) announced the approval of Surfaxin (lucinactant) for the prevention of respiratory distress syndrome in premature infants. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here